BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Agilent expands tumour profiling portfolio with SureSelect Cancer Research Pan Heme

November 20, 2026 | News

Integrated DNA and RNA profiling solution developed in collaboration with Roswell Park Comprehensive Cancer Center



Agilent Technologies Inc. has announced the launch of SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies.

Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow.

The introduction of SureSelect Cancer Research Pan Heme expands Agilent's tumour profiling portfolio for cancer research, providing a purpose-built solution for comprehensive profiling of hematologic tumors alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for ultra-comprehensive profiling for research across cancer types.

SureSelect Cancer Research Pan Heme interrogates 359 DNA genes and 124 RNA genes and assesses major classes of genomic alterations, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), IGH/IGK/IGL translocations and gene fusions. The solution combines Agilent SureSelect target enrichment technology with automated workflow options and integrated analysis capabilities.

SureSelect Cancer Research Pan Heme can be paired with the Agilent Magnis NGS Prep System for fully automated library preparation and target enrichment. Magnis uses prefilled, cartridge-based reagents to simplify workflow setup and enables walkaway operation, allowing laboratories to extend processing into unattended and overnight hours.